medigraphic.com
Medicina Universitaria

2007, Number 37

<< Back Next >>

Med Univer 2007; 9 (37)

Heart surgery

Ruiz DGJ, Mancías GC, González CML, Ojeda LY, Calderón GED, Marín LA, González LO, Gómez AD, Ruiz AGJ

Language: Spanish
References: 22
Page: 112-116
PDF size: 132.55 Kb.


ABSTRACT

Background: Umbilical cord blood cell transplantation is employed more frequently in the treatment of patients with hematologic malignancies. The number of hematopoietic cells in the cord limits its use and, as a result, stem cells from more than one cord are now being allografted.
Objective: To determine the viability of transplantation of hematopoietic cells form the umbilical cord of two donors.
Patients and method: We allografted five individuals, four of them with advanced hematologic diseases, with placental blood derived from two different cords in each case, using the “Mexican method” of non-ablative conditioning. Patient’s age went from 5 to 40 years. A total of 0.7 to 4.7 x 106 (median 2.02 x 106) CD34 cells from the two cords were grafted to each patient.
Results: Median time to reach above the 0.5 x 109/L granulocytes was 24 days, whereas median time to recover above 20 x 109/L platelets was 31 days. In 4 patients the graft did not take and in two patients mixed chimerism (40 and 70%) was shown after the allograf. In both instances the adoptive hematopoiesis was derived from only one of the two allografted cords. Three patients died, one of them as a result of graft versus host disease. The global survival rate at three months was 40% and the median survival rate was 37 days. These are the first five patients allografted with two cords in México.


REFERENCES

  1. Shander A, Moskowitz D, Rijhwani TS. The safety and efficacy of “bloodless” cardiac surgery. Semin Cardiothorac Vasc Anesth 2005;9:53-63.

  2. Engoren MC, Habib RH, Zacharias A, Schwann TA, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002;74:1180-6.

  3. Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel A, Herruzo- Aviles A, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001;119:1461-8.

  4. Chelemer SB, Prato BS, Cox PM, O’Connor GT, et al. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002;73:138-42.

  5. Stover EP, Siegel LC, Parks R, Levin J, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology 1998;88:327- 33.

  6. Moskowitz DM, Klein JJ, Shander A, Cousineau KM, et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center. Ann Thorac Surg 2004;77:626-34.

  7. Surgenor DM, Wallace EL, Churchill WH, Hao SH, et al. Red cell transfusion in coronary artery bypass graft surgery. (DRGs 106 an 107). Transfusion 1992;32:458-64.

  8. Wallace EL, Churchill WH, Surgenor DM, Cho GS, et al. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998;38:625-36.

  9. Colleen GK, Liang L, Andra ID, Tomislav M, et al. Morbidity and mortality risk associated with red blood cell and bloodcomponent transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006;34:1608-16.

  10. Rosengart TK, Helm RE, DeBois WJ, Garcia N, et al. Open heart operations without transfusion using a multimodality blood conservation strategy in 50 Jehovah’s Witness patients: implications for a “bloodless” surgical technique. J Am Coll Surg 1997;184:618-29.

  11. Helm RE, Rosengart TK, Gomez M. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998;65:125-36.

  12. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004;43:963-81.

  13. Sowade O, Warnke H, Scigalla P, Sowade B, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 1997;89:411-8.

  14. Goodnough LT, Despotis GJ, Parvin CA. Erythropoietin therapy in patients undergoing cardiac operations. Ann Thorac Surg 1997;64:1579-80.

  15. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there a reason? Chest 1995;108:767-71.

  16. Helm RE, Klemperer JD, Rosengart TK, Gold JP, et al. Intraoperative autologous blood donation preserves red cell mass but does not decrease postoperative bleeding. Ann Thorac Surg 1996;62:1431-41.

  17. DeBois WJ, Sukhram Y, McVey J. Eduction in homologous blood transfusion using a low prime circuit. J Extracorpor Technol 1996;28:58-66.

  18. DeFoe GR, Ross CS, Olmstead EM, Surgenor SD, et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 2001;71:769-76.

  19. Mangano DT, Tudor JC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.

  20. Hedner U. Recombinant factor VIIa (Novoseven) as a haemostatic agent. Semin Hematol 2001;38:43-47.

  21. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002;42:114-24.

  22. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000;11:S121-7.




2020     |     www.medigraphic.com